Literature DB >> 27853898

Rate and Predictors of Mucosal Healing in Ulcerative Colitis Treated with Thiopurines: Results of a Multicentric Cohort Study.

Caroline Prieux-Klotz1, Stéphane Nahon2, Aurelien Amiot3, Leila Sinayoko4, Carole Galéano-Cassaz5, Stanislas Chaussade6, Romain Coriat6, Pierre Lahmek7, Vered Abitbol6.   

Abstract

BACKGROUND AND AIMS: Mucosal healing (MH) with thiopurines has been poorly investigated in ulcerative colitis (UC). We aimed to assess MH rate in UC patients treated with thiopurine monotherapy. PATIENTS AND METHODS: We retrospectively collected all UC patients treated with thiopurines more than 6 months who have undergone colonoscopy at baseline and after at least 6 months of treatment. Patients were recruited from January 2005 to May 2015 through a personal database and/or standardized hospital inpatient diagnostic dataset. Patients were excluded in case of any use of other immunomodulator or biological agent. MH was defined as a Mayo endoscopic subscore ≤1 and UCEIS ≤ 2. Histological healing (HH) was defined by the absence of epithelial polynuclear infiltrate, cryptic abscesses, or ulcerations.
RESULTS: Eighty patients (31 women, median age 43 [IQR 32-58]) were included. Median disease duration was 10.5 [6-16] years. At baseline, median full Mayo score, endoscopic subscore, and UCEIS were 8 [6.8-10], 3 [2-3], and 5 [3-6], respectively. MH was first assessed after a mean follow-up of 38 ± 31 months. Median full Mayo score, endoscopic subscore, and UCEIS decreased to 3.5 [1-6], 2 [0-2.2], and 2 [0-4], respectively. MH was achieved in 43.7%, HH in 38%. In multivariate analysis, predictors of MH were thiopurine exposure duration ≥2 years [odds ratio (OR) 2.9, CI 95% (1.1-7.6), p = 0.03] and a prior acute severe colitis [OR 5.9, CI 95% (1.1-32), p = 0.04]. Factors associated with MH during treatment were partial Mayo score ≤2 (NPV = 100%), BMI ≥ 25 kg/m2 (NPV = 75%), and MCV ≥ 95 fL (NPV = 73%).
CONCLUSIONS: In UC, thiopurine monotherapy is associated with MH in 43.7% and HH in 38%.

Entities:  

Keywords:  Azathioprine; Histological healing; Mayo score; Mercaptopurine; Mucosal healing; Thiopurine; UCEIS; Ulcerative colitis

Mesh:

Substances:

Year:  2016        PMID: 27853898     DOI: 10.1007/s10620-016-4374-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  38 in total

1.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

2.  Reliability and initial validation of the ulcerative colitis endoscopic index of severity.

Authors:  Simon P L Travis; Dan Schnell; Piotr Krzeski; Maria T Abreu; Douglas G Altman; Jean-Frédéric Colombel; Brian G Feagan; Stephen B Hanauer; Gary R Lichtenstein; Philippe R Marteau; Walter Reinisch; Bruce E Sands; Bruce R Yacyshyn; Patrick Schnell; Christian A Bernhardt; Jean-Yves Mary; William J Sandborn
Journal:  Gastroenterology       Date:  2013-07-25       Impact factor: 22.682

3.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.

Authors:  Walter Reinisch; William J Sandborn; Daniel W Hommes; Geert D'Haens; Stephen Hanauer; Stefan Schreiber; Remo Panaccione; Richard N Fedorak; Mary Beth Tighe; Bidan Huang; Wendy Kampman; Andreas Lazar; Roopal Thakkar
Journal:  Gut       Date:  2011-01-05       Impact factor: 23.059

4.  Long-term efficacy and safety of azathioprine in ulcerative colitis.

Authors:  Ruchit Sood; Saqib Ansari; Tanya Clark; P John Hamlin; Alexander C Ford
Journal:  J Crohns Colitis       Date:  2015-02       Impact factor: 9.071

5.  Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis.

Authors:  James D Lewis; Shaokun Chuai; Lisa Nessel; Gary R Lichtenstein; Faten N Aberra; Jonas H Ellenberg
Journal:  Inflamm Bowel Dis       Date:  2008-12       Impact factor: 5.325

6.  Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.

Authors:  Matthew Rutter; Brian Saunders; Kay Wilkinson; Steve Rumbles; Gillian Schofield; Michael Kamm; Christopher Williams; Ashley Price; Ian Talbot; Alastair Forbes
Journal:  Gastroenterology       Date:  2004-02       Impact factor: 22.682

7.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

Authors:  Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2014-02       Impact factor: 22.682

8.  Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up.

Authors:  Robert V Bryant; Daniel C Burger; Joseph Delo; Alissa J Walsh; Sally Thomas; Axel von Herbay; Otto C Buchel; Lydia White; Oliver Brain; Satish Keshav; Bryan F Warren; Simon P L Travis
Journal:  Gut       Date:  2015-05-18       Impact factor: 23.059

9.  Clinical Study of the Relation between Mucosal Healing and Long-Term Outcomes in Ulcerative Colitis.

Authors:  Kaoru Yokoyama; Kiyonori Kobayashi; Miyuki Mukae; Miwa Sada; Wasaburo Koizumi
Journal:  Gastroenterol Res Pract       Date:  2013-05-09       Impact factor: 2.260

Review 10.  Clinical pharmacology and pharmacogenetics of thiopurines.

Authors:  Srikumar Sahasranaman; Danny Howard; Sandip Roy
Journal:  Eur J Clin Pharmacol       Date:  2008-05-28       Impact factor: 3.064

View more
  4 in total

1.  Enduring Value of Thiopurines for Inflammatory Bowel Disease Therapy.

Authors:  Burton I Korelitz
Journal:  Dig Dis Sci       Date:  2017-02       Impact factor: 3.199

2.  Thiopurine Monotherapy Is Effective in Maintenance of Mild-Moderate Inflammatory Bowel Disease.

Authors:  Grant E Barber; Steven Hendler; Monica Choe; Kian Keyashian; Sarah Lechner; Berkeley N Limketkai; David Limsui
Journal:  Dig Dis Sci       Date:  2021-03-23       Impact factor: 3.199

3.  Sustained Clinical Efficacy and Mucosal Healing of Thiopurine Maintenance Treatment in Ulcerative Colitis: A Real-Life Study.

Authors:  Daniela Pugliese; Annalisa Aratari; Stefano Festa; Pietro Manuel Ferraro; Rita Monterubbianesi; Luisa Guidi; Maria Lia Scribano; Claudio Papi; Alessandro Armuzzi
Journal:  Gastroenterol Res Pract       Date:  2018-10-03       Impact factor: 2.260

4.  Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.

Authors:  Adérson Omar Mourão Cintra Damião; Matheus Freitas Cardoso de Azevedo; Alexandre de Sousa Carlos; Marcela Yumi Wada; Taciana Valéria Marcolino Silva; Flávio de Castro Feitosa
Journal:  World J Gastroenterol       Date:  2019-03-07       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.